萝卜硫素在女性恶性肿瘤中的作用及机制研究进展

Research progress on the role and mechanism of Sulforaphane in female malignant tumors

ES评分 0

DOI 10.12208/j.ijcr.20230330
刊名
International Journal of Clinical Research
年,卷(期) 2023, 7(10)
作者
作者单位

延安大学附属医院 陕西延安 ;

摘要
现代药理学研究表明,异硫氰酸酯家族(ITCs)作为抗癌剂具有巨大潜力。ITCs可以通过调节涉及致癌物生物转化和解毒、炎症、细胞周期、细胞凋亡和表观遗传调控的多种信号通路来抑制癌变并抑制肿瘤生长。萝卜硫素作为ITCs的成员之一,具有许多预防癌症的特性,它能促进程序性细胞死亡/凋亡、诱导细胞周期停滞、抑制血管生成、抗炎、降低对致癌物的易感性、减少肿瘤细胞侵袭和转移,并表现出抗氧化和抗炎特性。近年来四大常见的女性恶性肿瘤乳腺癌、宫颈癌、子宫内膜癌、卵巢癌发病率较前上升,严重危害着女性的身心健康。而萝卜硫素在此范围内研究较少,因此,本篇综述通过介绍萝卜硫素在乳腺癌、宫颈癌、子宫内膜癌、卵巢癌中的作用及可能机制,以期为女性恶性肿瘤的临床治疗提供新线索。
Abstract
Modern pharmacological studies have shown that the Isothiocyanate family(ITCs) has great potential as anticancer agents. ITCs can inhibit carcinogenesis and inhibit tumor growth by regulating multiple signaling pathways involved in carcinogenic biotransformation and detoxification, inflammation, cell cycle, apoptosis, and epigenetic regulation. Sulforaphane, as a member of the Isothiocyanate family, has many cancer-preventing properties, it promotes programmed cell death/apoptosis, induces cell cycle arrest, inhibits angiogenesis, is anti-inflammatory, reduces susceptibility to carcinogens, reduces tumor cell invasion and metastasis, and exhibits antioxidant and anti-inflammatory properties. In recent years, the incidence of four common female malignant tumors, breast cancer, cervical cancer, endometrial cancer and ovarian cancer, has increased, seriously endangering the physical and mental health of women. However, there are few researches on sulforaphane in this scope. Therefore, this review introduces the role and possible mechanism of sulforaphane in breast cancer, cervical cancer, endometrial cancer and ovarian cancer, hoping to provide new clues for the clinical treatment of female malignant tumors.
关键词
萝卜硫素;异硫氰酸酯;乳腺癌;宫颈癌;子宫内膜癌;卵巢癌
KeyWord
Sulforaphane; Isothiocyanate; Breast cancer; Cervical cancer; Endometrial cancer; Ovarian cancer
基金项目
页码 31-35
  • 参考文献
  • 相关文献
  • 引用本文

刘开开,李红霞*,王萌倩,刘芯瑜,张晓露. 萝卜硫素在女性恶性肿瘤中的作用及机制研究进展 [J]. 国际临床研究杂志. 2023; 7; (10). 31 - 35.

  • 文献评论

相关学者

相关机构